State of Biotech in Cambridge, MA 2026

7 funded Biotech companies in Cambridge, MA, backed most often by Flagship Pioneering, Arca, Light Ray Ventures — verified cap-table data for 2026.

Biotech in Cambridge, MA accounts for 43 tracked companies with verified cap-table data, 43 of which disclose round sizes totalling $7.9B. The median disclosed raise is $115M, and the largest is Beam Therapeutics at $1B, ahead of Hemab ($537M) and Parabilis Medicines ($500M).

The names that recur most often on these biotech cap tables are Atlas Venture (9 companies), RA Capital Management (8 companies), Flagship Pioneering (5 companies), Khosla Ventures (4 companies), Catalio Capital Management (4 companies), Third Rock Ventures (4 companies). By latest disclosed round, the market skews Series A (20), Series B (7), Series C (5), Seed (4).

Best funded Biotech in Cambridge, MA companies

  1. Beam Therapeutics — $1B (latest: IPO)
  2. Hemab — $537M (latest: IPO)
  3. Parabilis Medicines — $500M (latest: Series F)
  4. EGenesis — $481M (latest: Series D)
  5. Vor Biopharma — $400M
  6. FogPharma — $323M (latest: Series D)
  7. Apollo Therapeutics — $260M (latest: Series C)
  8. ARTBIO — $245M (latest: Series B)
  9. City Therapeutics — $235M (latest: Series A)
  10. Editas Medicine — $214M (latest: IPO)
  11. Aviceda Therapeutics — $210M (latest: Series C)
  12. Obsidian Therapeutics — $200M (latest: Series C)
  13. Arbor Biotechnologies — $200M (latest: Series C)
  14. Lila Sciences — $200M (latest: Seed)
  15. Harbinger Health — $190M (latest: Series B)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library